The future of the UK’s £70bn ($89bn) health care industry was uncertain amid a record number of mergers and acquisitions and ahead of Brexit uncertainty. Britain’s biggest drugs group said it would be “disappointed” if its rivals were allowed to buy AstraZeneca. The scale of those mergers and acquisitions has forced politicians, scientists, entrepreneurs and investors alike to sit up and take notice. Global health care deals were also heading towards their own $474bn record. The UK government said health care was at the centre of its industrial strategy. The sector has warned about the threat to it of a no-deal Brexit. The Association of the British Pharmaceutical Industry and Bio Industry Association said there was a lack of clarity in the Brexit deal about the future.
The future of the UK’s £70bn ($89bn) health care industry was uncertain amid a record number of mergers and acquisitions and ahead of Brexit uncertainty. Britain’s biggest drugs group said it would be “disappointed” if its rivals were allowed to buy AstraZeneca. Global health care deals were also heading towards their own $474bn record. The UK government said health care was at the centre of its industrial strategy. The sector has warned about the threat to it of a no-deal Brexit. The Association of the British Pharmaceutical Industry and Bio Industry Association said there was a lack of clarity in the Brexit deal about the future.